Impact Of Dapagliflozin To Prevent Contrast Induced Nephropathy After Heart Catheterization And Percutaneous Coronary Intervention

Background: Contrast-induced nephropathy (CIN) is a potential complication that can occur afterward heart catheterization & percutaneous coronary intervention (PCI), particularly in cases with comorbid conditions like diabetes and chronic kidney disease. CIN is characterized by a rapid loss in kidney function after treatment with contrast agents during these procedures. It is linked with higher morbidity, mortality, and healthcare expenditures. Therefore, finding effective preventive measures for CIN is crucial. Aim and objectives: To determine the role of Dapagliflozin in CIN following cardiac catheterization and PCI. Subjects and methods: A prospective research was performed at the Department of Cardiology, Faculty of Medicine, Al-Azhar University,Cairo, Egypt. The research involved 400 cases Separated into 3 groups. Results: There was statistically non-substantial distinction the examined groups concerning gender or age.There was statistically substantial relation between development of CIN & all of procedure and between eGFR baseline & follow up. Conclusion: Dapagliflozin for the prevention of CIN during cardiac catheterization and PCI was well tolerated and achieved the desired results. Based on the results of our research, SGLT2 inhibitors may offer protection against CIN, particularly in individuals with co-morbidities like diabetes. Comorbid heart failure, higher baseline serum creatinine and non-use of dapagliflozin significantly independently increase risk of CIN.